MEENAKSHI PARMAR: Open Payments
NPI 1417170143 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$944 in 36 payments from 18 companies in 2025. Trend: 2023 $118 · 2024 $122 · 2025 $944
Food & beverage: $944
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 2 | $143 |
| E.R. Squibb & Sons, L.L.C. | 2 | $132 |
| Otsuka America Pharmaceutical, Inc. | 5 | $109 |
| TG Therapeutics, Inc. | 4 | $92 |
| Tris Pharma Inc | 4 | $71 |
| Collegium Pharmaceutical, Inc. | 3 | $59 |
| ABBVIE INC. | 3 | $56 |
| ACADIA Pharmaceuticals Inc | 2 | $52 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Neurocrine BioSciences, Inc. | 1 | $29 |
Products named: COBENFY, LYBALVI, BRIUMVI, REXULTI, Dyanavel XR, Jornay PM, VRAYLAR, NUPLAZID.
Industry payments across GA — which companies pay providers there.
